Related Experiment Video
Updated: Aug 19, 2026

Preclinical Positron Emission Tomography with Body Conforming Animal Molds for Cloud-Based Automated Image Analysis in Mice
Published on: October 25, 2024
Using imaging biomarkers to accelerate drug development and clinical trials
Homer H Pien1, Alan J Fischman, James H Thrall
1Department of Radiology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA. hpien@nmr.mgh.harvard.edu
Abstract:
There is increasing evidence that human medical imaging can help answer key questions that arise during the drug development process. Imaging modalities such as magnetic resonance imaging, computed tomography and positron emission tomography can offer significant insights into the bioactivity, pharmacokinetics and dosing of drugs, in addition to supporting registration applications. In this review, examples from oncology, neurology, psychiatry, infectious diseases and inflammatory diseases are used to illustrate the role imaging can play. We conclude with some remarks concerning new developments that will be required to significantly advance the field of pharmaco-imaging.
Related Concept Videos
Brain Imaging
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).
Pharmacogenomics: Identification of New Drug Targets
Clinical Trials: Overview
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...
